In this articlePFEMTSRThomas Fuller | SOPA Images | Lightrocket | Getty ImagesA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Pfizer's newest bet on obesity is already showing promise. The company last week said it would buy weight loss drugmaker Metsera in an up to $7.3 billion deal, including future payments, that is expected to close at the end of the year. Just a week ...

Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones. ...

9月29日，Metsera(MTSR.US)(已被辉瑞(PFE.US)收购)宣布MET-097i的两项减重IIb期研究(VESPER-1和 VESPER-13)取得了积极结果。MET-097i是一种同类首创的完全偏向、超长效GLP-1受体激动剂(GLP-1- RA)，具有每月注射1次的给药潜力。Metsera认为，MET-097i可以在稳态下与15mg替尔泊肽的性能相匹 敌或超过，并计划在年底之前启动III期临床试验。 ...

Metsera said on Monday that its experimental obesity drug showed significant weight loss and favorable tolerability in mid-stage studies. ...

Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and treatment retention in both VESPER-1 and VESPER-3 trials Data support Phase 3 initiation in late 2025 NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from VESPER-1 and positive data from a planned interim analysis for tolerability of VESPER-3 – two Phas ...

Leerink downgraded Metsera (MTSR) to Market Perform from Outperform with a price target of $57, down from $77, after Pfizer (PFE) announced an agreement to acquire Metsera for $4.9B upfront and total potential deal value of about $7.3B contingent on hitting various pipeline-related targets. Metsera’s novel obesity pipeline should help drive Pfizer revenue growth beyond 2028, says the analyst, who believes Metsera’s assets could collectively generate greater than $5B in peak sales. Elevate Your Investing S ...

Core Viewpoint - Pfizer plans to acquire Metsera for $4.9 billion, with potential total value reaching $7.3 billion including milestone payments, aiming to strengthen its position in the obesity drug market projected to be worth $100 billion by 2030 [1][3]. Group 1: Acquisition Details - The acquisition price is set at $47.50 per share, with milestone payments potentially increasing the total to $70 per share [1]. - Metsera's stock surged by 60% to over $50 following the acquisition announcement, while Pfizer's stock remained stable around $24 [2]. - Pfizer will finance the acquisition through cash and debt, while maintaining its dividend and capital priorities [2]. Group 2: Market Context - The obesity drug market is currently dominated by Eli Lilly and Novo Nordisk, with Eli Lilly's Zepbound controlling over 50% of the market and achieving an average weight reduction of 20.2%, compared to Novo Nordisk's Wegovy at 13.5% [4]. - Pfizer previously discontinued its own obesity drug, danuglipron, due to safety concerns [4]. Group 3: Financial Implications - The acquisition could help Pfizer mitigate the impact of upcoming patent expirations for key drugs like Eliquis and Ibrance [5]. - Metsera has raised $316.2 million through its IPO but is not expected to generate significant revenue in the near future [6]. - Pfizer's total sales are projected to slightly increase to $63.81 billion in the current year, with a slight decline expected in FY26 [12]. Group 4: Drug Pipeline - Metsera's MET-097i weight loss drug is in phase two trials, targeting hormones for weight loss and type 2 diabetes treatment [7]. - Metsera's MET-233i drug has shown promising results with an average weight loss of 8.4% in the first five weeks of phase 1 trials [7]. Group 5: Earnings Projections - Pfizer's EPS for FY25 is projected to increase to $3.14, while FY26 EPS is expected to decline to $3.08 [12]. - Metsera's FY25 EPS estimates have improved to a projected loss of -$2.79 per share, but FY26 estimates have worsened to -$3.64 [16].

Accessibility StatementSkip Navigation NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Metsera, Inc. (NASDAQ: MTSR) related to its sale to Pfizer Inc. Under the terms of the pr ...

We recently published 10 Stocks Stealing Wall Street’s Spotlight. Metsera Inc. (NASDAQ:MTSR) is one of the top performers on Monday. Shares of Metsera Inc. (NASDAQ:MTSR) jumped to a new all-time high on Monday, as investors gobbled up shares following news that it was set to be acquired by Pfizer Inc. (NYSE: PFE) for a potential transaction value of more than $7 billion. During the session, Metsera Inc. (NASDAQ:MTSR) soared to its highest price of $54.46 before trimming gains to close the day just up by ...

Core Insights - Pfizer (PFE) has announced a definitive agreement to acquire Metsera (MTSR), a developer of obesity drugs, to re-enter the obesity market after discontinuing its own weight-loss pill, danuglipron [1][5]. Company Summary - Pfizer will acquire Metsera's shares for $47.50 per share, totaling an enterprise value of $4.9 billion, with an additional contingent value right (CVR) of up to $22.50 per share based on clinical and regulatory milestones [2][10]. - The acquisition includes Metsera's four clinical-stage programs, notably the GLP-1 receptor agonist MET-097i, which is currently in phase II studies [3][10]. - The boards of both companies have unanimously approved the transaction, expected to close in Q4 2025, pending shareholder approvals [4]. Industry Summary - The obesity market is projected to grow to $100 billion by 2030, with Eli Lilly (LLY) and Novo Nordisk (NVO) currently leading the market with their GLP-1 injections [6]. - Other companies, including Amgen and Viking Therapeutics, are also developing advanced GLP-1-based candidates in late-stage studies [7]. - Metsera's products are in early development stages, with potential market entry around 2028-2029, indicating that Pfizer may lag behind competitors in this highly competitive space [8]. - Other large pharmaceutical companies, such as AbbVie, Roche, and Merck, are also entering the obesity market through licensing deals with smaller biotech firms [9][11][12].